睿知中国医院研究地图
候选清单

即将招募淋巴瘤I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07638787,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Patients with newly diagnosed large B-cell lymphoma confirmed by histopathology, CD20-positive, excluding central nervous system lymphoma;

    入选标准第 1 条

    Measurable lesions confirmed by radiological examination, defined as: at least one lymph node lesion with the longest diameter > 1.5 cm, or at least one extranodal lesion with the longest diameter > 1.0 cm, and at least two accurately measurable perpendicular diameters;

    入选标准第 8 条

  3. Participants with a history of untreated low-grade early-stage prostate cancer (Gleason score ≤ 6, Stage 1 or 2) at any time before the study are eligible to participate;

    排除标准第 19 条

  4. Participants who received adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer for ≥ 2 years before enrollment are eligible to participate;

    排除标准第 20 条

    History of immune-related adverse events following prior immunotherapy drug-related treatment, as follows: known active bacterial, viral, fungal, mycobacterial, parasitic, or other infections (excluding onychomycosis) at study enrollment, or major infections within 4 weeks before the start of Cycle 1;

    排除标准第 22 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;

    入选标准第 7 条

  6. Neutrophils < 1.0×10⁹/L;

    排除标准第 5 条

    Platelets < 75×10⁹/L;

    排除标准第 6 条

    Serum AST and ALT ≥ 2.5× upper limit of normal (ULN);

    排除标准第 7 条

    Total bilirubin ≥ 1.5×ULN;

    排除标准第 8 条

    Serum creatinine clearance < 30 mL/min (calculated using the Cockcroft-Gault formula);

    排除标准第 9 条

  7. Patients infected with human immunodeficiency virus (HIV);

    排除标准第 16 条

    Active hepatitis B virus (HBV) infection (positive result by PCR). For patients with positive HBsAg test results, HBV DNA test is required; if HBV DNA < 10³ IU/ml, they can be enrolled. If HBsAg test result is negative but HBcAb test is positive (regardless of HBsAb status), HBV DNA test is also required; if HBV DNA < 10³ IU/ml, they can be enrolled;

    排除标准第 23 条

    Positive hepatitis C test result (serological test for hepatitis C virus [HCV] antibody):

    排除标准第 24 条

    Eligibility to participate is only allowed if the PCR test result for HCV RNA is negative in patients with positive HCV antibody;

    排除标准第 25 条

  8. Currently pregnant or breastfeeding, or planning to become pregnant during the study or within 12 months after the last dose;

    排除标准第 27 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07638787,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients with newly diagnosed large B-cell lymphoma confirmed by histopathology, CD20-positive, excluding central nervous system lymphoma;
  2. Patients aged 18 to 75 years;
  3. International Prognostic Index score of 2 to 5;
  4. Patients with high BCL-2 expression or double-hit lymphoma characteristics;
  5. No prior anti-tumor treatment of any type;
  6. Estimated survival time ≥ 6 months;
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;
  8. Measurable lesions confirmed by radiological examination, defined as: at least one lymph node lesion with the longest diameter > 1.5 cm, or at least one extranodal lesion with the longest diameter > 1.0 cm, and at least two accurately measurable perpendicular diameters;
  9. Patients or their legal representatives must provide written informed consent before conducting any study-specific examinations or procedures;
  10. No prior treatment for lymphoma (except glucocorticoids).

排除标准:Exclusion Criteria:

  1. Prior solid organ transplantation or stem cell transplantation;
  2. Complicated with uncontrolled coagulation disorders, connective tissue diseases, severe infectious diseases, etc.;
  3. Suspected active or latent tuberculosis (confirmed by a positive interferon-gamma release assay);
  4. Any of the following abnormal laboratory test values (unless these abnormalities are all caused by the underlying lymphoma):
  5. Neutrophils < 1.0×10⁹/L;
  6. Platelets < 75×10⁹/L;
  7. Serum AST and ALT ≥ 2.5× upper limit of normal (ULN);
  8. Total bilirubin ≥ 1.5×ULN;
  9. Serum creatinine clearance < 30 mL/min (calculated using the Cockcroft-Gault formula);
  10. Uncontrolled or significant cardiovascular diseases, including but not limited to:
  11. Left ventricular ejection fraction (LVEF) < 50%;
  12. Primary cardiomyopathy, such as dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, etc.;
  13. Clinically significant QTc prolongation, with QTc interval > 470 ms (females) or 480 ms (males), second-degree type II atrioventricular block, or third-degree atrioventricular block;
  14. Current or past history of central nervous system (CNS) diseases, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative diseases. However, participants with a history of stroke who have not had a stroke or transient ischemic attack in the past 2 years and have no residual neurological deficits as judged by the investigator are allowed to participate in the study;
  15. Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol;
  16. Patients infected with human immunodeficiency virus (HIV);
  17. History of other malignant tumors that may affect protocol compliance or interpretation of results:
  18. Participants with a history of cured basal or squamous cell carcinoma of the skin, melanoma, or carcinoma in situ of the cervix at any time before the study are eligible to participate;
  19. Participants with a history of untreated low-grade early-stage prostate cancer (Gleason score ≤ 6, Stage 1 or 2) at any time before the study are eligible to participate;
  20. Participants who received adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer for ≥ 2 years before enrollment are eligible to participate;
  21. Participants with any other malignant tumor cured by appropriate radical treatment and in remission without treatment for ≥ 2 years before enrollment are eligible to participate;
  22. History of immune-related adverse events following prior immunotherapy drug-related treatment, as follows: known active bacterial, viral, fungal, mycobacterial, parasitic, or other infections (excluding onychomycosis) at study enrollment, or major infections within 4 weeks before the start of Cycle 1;
  23. Active hepatitis B virus (HBV) infection (positive result by PCR). For patients with positive HBsAg test results, HBV DNA test is required; if HBV DNA < 10³ IU/ml, they can be enrolled. If HBsAg test result is negative but HBcAb test is positive (regardless of HBsAb status), HBV DNA test is also required; if HBV DNA < 10³ IU/ml, they can be enrolled;
  24. Positive hepatitis C test result (serological test for hepatitis C virus [HCV] antibody):
  25. Eligibility to participate is only allowed if the PCR test result for HCV RNA is negative in patients with positive HCV antibody;
  26. Participants with a history of progressive multifocal leukoencephalopathy (PML);
  27. Currently pregnant or breastfeeding, or planning to become pregnant during the study or within 12 months after the last dose;
  28. Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study.

引自 ClinicalTrials.gov, NCT07638787, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07638787,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07638787